Receptor-interacting protein 1 (RIP1) is a Ser/Thr kinase with both kinase-dependent and kinase-independent roles in death receptor signaling. The kinase activity of RIP1 is required for necroptosis, a caspase-independent pathway of programmed cell death. In some cell types, the inhibition of caspases leads to autocrine production of TNFa, which then activates necroptosis. Here, we describe a novel role for RIP1 kinase in regulating TNFa production after caspase inhibition. Caspase inhibitors activate RIP1 kinase and another protein, EDD, to mediate JNK signaling, which stimulates Sp1-dependent transcription of TNFa. This pathway is independent of nuclear factor jB and also occurs after Smac mimetic/IAP antagonist treatment or the loss of TNF receptor-associated factor 2 (Traf2). These findings implicate cIAP1/2 and Traf2 as negative regulators of this RIP1 kinasedependent TNFa production pathway and suggest a novel role for RIP1 kinase in mediating TNFa production under certain conditions.
Receptor-interacting protein 1 (RIP1) is a multi-functional signal transducer involved in mediating nuclear factor kB (NF-kB) activation, apoptosis, and necroptosis. The kinase activity of RIP1 is critically involved in mediating necroptosis, a caspaseindependent pathway of necrotic cell death. 1,2 RIP1 kinase and necroptosis are activated by death receptor ligands, such as TNFa and Fas, when apoptosis is blocked. 1, 3 Necrostatin-1 (Nec-1), a small molecule inhibitor of RIP1 kinase activity, can also block necroptosis. In some cell types, such as mouse fibrosarcoma L929 cells, necroptosis is activated by inhibition of caspase activity using a pan-caspase inhibitor such as zVAD.fmk. 3 How RIP1 kinase is activated to mediate necroptosis induced by caspase inhibition is not clear. RIP1 is ubiquitinated by the cellular inhibitor of apoptosis proteins, cIAP1 and cIAP2. 4, 5 RIP1 is ubiquitinated by a number of other E3 ubiquitin ligases as well, suggesting that RIP1 ubiquitination might regulate RIP1 activity. Smac mimetics (SMs) are a class of compounds modeled after the N terminus of a cellular protein, Smac/DIABLO, that inhibits the IAPs. SMs are under development as anti-cancer drugs. 6, 7 In some cell types, SM treatment can induce autocrine TNFa production and cell death, although the pathway has not been fully elucidated. [7] [8] [9] [10] TNFa is an important pro-inflammatory cytokine involved in mediating cell death and inflammation in many human diseases such as rheumatoid arthritis and cancers. In a genome-wide siRNA screen to identify genes involved in necroptosis, we found that knockdown of tnfr1 or treatment with a TNFa-neutralizing antibody was protective against zVAD.fmk-induced cell death in L929 cells, indicating that zVAD.fmk was likely inducing autocrine TNFa production. 11 As knockdown of RIP1 protects against zVAD.fmk-induced death, 11 we tested the hypothesis that RIP1 might act upstream of TNFa production after zVAD.fmk and identified a novel function of RIP1 kinase in mediating TNFa production.
EDD/UBR5/hHYD is a putative tumor suppressor and HECT (homologous to E6-AP C-terminus)-domain-containing E3 ubiquitin ligase implicated in cellular pathways including the regulation of gene expression, the DNA damage response, and in necroptosis after it was identified in a siRNA screen. 11, 12 EDD regulates gene expression transcriptionally, by forming complexes with transcription factors, and translationally by regulating protein levels of Paip2, a poly-A-binding protein inhibitor. 13, 14 EDD is also important in the cellular DNA damage response, mediating ATM phosphorylation of its substrates CHK2 and p53 after DNA damage to control cell cycle arrest. [15] [16] [17] Given its multiple functions in mediating cellular processes, EDD likely acts as a chaperone protein, coordinating the various protein complexes involved in different cellular pathways.
In this study, we describe a novel RIP1 kinase-dependent TNFa production pathway occurring in cellular models of necroptosis and apoptosis. We explored this novel TNFa production pathway using a combination of chemical inhibitors and genetic analysis, and defined a protein complex containing EDD, RIP1, and cIAP1 that mediates JNK activation and transcription of TNFa. This TNFa production pathway requires RIP1 kinase and is activated specifically in response to zVAD.fmk stimulation, SM compounds, or TNF receptorassociated factor 2 (Traf2) deficiency.
Results
RIP1 and EDD are required for TNFa production in response to zVAD.fmk. To directly examine whether zVAD.fmk stimulates the production of TNFa, we measured TNFa levels after zVAD.fmk treatment. TNFa could be detected in dying L929 cells treated with zVAD.fmk. Nec-1, a RIP1 kinase inhibitor, blocked the increase in TNFa protein levels as well as cell death (Figures 1a and b) .
As the knockdown of RIP1 can have differential effects from the inhibition of its kinase activity alone, 11 we used Nec-1 as a tool to examine the role of RIP1 kinase in TNFa production. Although Nec-1 has been shown to be a specific inhibitor of RIP1 kinase, 2 we further tested the specificity of Nec-1 to ensure its suitability for this study. Nec-1 specifically binds RIP1 with K d 5.6 nM for racemic Nec-1 and K d 3.1 nM for R-Nec-1 (Supplementary Figure S1a ). Using KINOMEscan (Ambit Biosciences, San Diego, CA, USA), 18 Nec-1 (10 mM) was tested for activity against 485 kinases and activated mutant kinases. When ranked in order of inhibition, RIP1 is the top kinase inhibited by Nec-1 (Supplementary Figure  S1b ). Aside from RIP1, no kinases were inhibited greater than 60% by Nec-1. PDGFRb was inhibited by 72%, however, the K d of binding of Nec-1 to PDGFRb was greater than 30 mM, suggesting a false positive ( Supplementary Figures S1a and  b ). Nec-1 is more specific than 35 known kinase inhibitors including imatinib (Gleevec) (Supplementary Figure S1c ). As further evidence, Nec-1 can only protect against necroptosis in Rip1 þ / þ MEF cells, but not in Rip1 À / À MEFs (Supplementary Figure S1d ). Thus, we conclude that Nec-1 is a highly specific inhibitor of RIP1 kinase activity and an appropriate tool with which to study the specific role of RIP1 kinase.
L929 cells are exquisitely sensitive to death induced by TNFa treatment, so to directly study the effect of RIP1 on TNFa production we tested different cell types that produce TNFa in response to zVAD.fmk treatment. A mouse macrophage cell line, J774, was found to produce easily measurable TNFa levels in response to zVAD.fmk stimulation (Figure 1c ). Both primary macrophages and macrophage cell lines undergo necroptosis in response to zVAD.fmk. 11, 19 Although J774 cell treatment with zVAD.fmk induced necroptosis, cell death was not dependent on the production of TNFa. Cell death was observed beginning at least 12 h after the increase in TNFa was first detected and neutralization of TNFa was not sufficient to block zVAD.fmk-induced necroptosis of J774 cells (Figure 1b ). Inhibition of RIP1 kinase by Nec-1 completely blocked the production of TNFa in J774 cells, suggesting that RIP1 kinase is required for TNFa production in zVAD.fmk-treated J774 cells ( Figure 1c ).
The production of TNFa in response to zVAD.fmk treatment was blocked by CHX suggesting that de novo protein synthesis is involved ( Figure 1d ). Consistent with this possibility, our siRNA screen found a significant enrichment of transcription factors and nucleic acid-binding genes among hits protecting against zVAD.fmk-induced necroptosis. 11 Treatment with zVAD.fmk activates de novo synthesis of TNFa though a mechanism dependent upon the kinase activity of RIP1.
To find additional components of the RIP1 kinase-dependent pathway of TNFa production, we identified RIP1-binding proteins. 293T cells were transfected with a vector expressing Flag-tagged RIP1 kinase, and RIP1 immunocomplexes were isolated using anti-Flag. The binding proteins were identified by mass spectrometry analysis. This analysis identified FADD, a known RIP1-binding protein, thus validating the To distinguish binding proteins that have a functional role in mediating the production of TNFa, we compared the list of mass spectrometry-identified proteins with the hits identified in the genome-wide siRNA screen for genes involved in mediating necroptosis of L929 cells in response to zVAD.fmk. 11 EDD, encoded by the gene edd1, is both a RIP1-binding protein and a gene whose knockdown blocks zVAD.fmk-induced necroptosis. We confirmed that RIP1 coimmunoprecipitated EDD (Figure 2a ). Interestingly, overexpression of EDD consistently increases the levels of exogenously expressed RIP1 protein but has no effect on endogenous RIP1, suggesting that overexpressed RIP1 is stabilized by EDD (Figure 2a , Supplementary Figure S2a ). Knockdown of EDD protected against zVAD.fmk but not TNFa-induced necroptosis (Figure 2b ), indicating EDD does not have any role in TNFa-induced necroptosis and instead has a likely role in zVAD.fmk-induced TNFa production. To determine whether EDD is required for TNFa production, we generated stable knockdown cell lines using retroviral infection of an shRNA construct against EDD. Knockdown of EDD inhibited zVAD.fmk-induced TNFa, demonstrating that EDD is required for TNFa production (Figure 2c ).
To determine how TNFa production is activated, we used real-time PCR to measure TNFa mRNA levels after zVAD.fmk treatment. Stimulation with zVAD.fmk increased TNFa mRNA, and treatment with Nec-1, or knockdown of EDD, was able to block the increase in TNFa mRNA ( Figure 2d ). Thus, RIP1 and EDD activate the transcription of TNFa after zVAD.fmk treatment.
SM induces TNFa in a manner dependent on RIP1 kinase and EDD. To explore the physiological relevance of this pathway, we looked for other stimuli that could also activate this RIP1 kinase-dependent pathway of TNFa production. SM induces autocrine TNFa production in some cells. 7-10 Thus, we tested whether RIP1 and EDD have role in SM-induced TNFa. Treatment with SM induces the auto-ubiquitination and degradation of cIAP1 and cIAP2, and also blocks XIAP binding to and inhibition of caspases. We tested the effect of the previously described SM-164 20,21 on L929 cells and found that, similar to zVAD.fmk, SM-164 induced TNFa-dependent necrotic cell death that could be inhibited by Nec-1 or a TNFaneutralizing antibody (Figure 3a ). Knockdown of RIP1, EDD, or TNFR1 was able to block SM-induced necroptosis, suggesting that SM might be activating the same RIP1-and EDD-dependent pathway of TNFa production as zVAD.fmk ( Figure 3b ). ELISA was used to detect an increase in TNFa in the lysate of SM-treated L929 cells. SM-induced TNFa could be inhibited by Nec-1 treatment and in EDD-knockdown cells, confirming that SM activates RIP1 kinase and EDD-dependent TNFa production ( Figure 3c ).
Traf2, an E3 ubiquitin ligase, is constitutively bound to cIAP1/2 within the cell. 22, 23 Traf2-knockout mice have elevated levels of serum TNFa, 24 which suggested to us that Traf2 might act similarly to cIAP1/2 to inhibit induction of TNFa. Indeed, knockdown of Traf2 in L929 cells induced TNFa-dependent necroptosis that could be blocked by both TNFa-neutralizing antibody or knockdown of TNFR1 ( Figure 3d ). Similar to SM-and zVAD.fmk-induced cell death, Traf2 knockdown-induced death could be blocked by Nec-1 and by knockdown of RIP1 or EDD ( Figure 3d ). Thus, the absence of Traf2, similar to the loss of cIAP1/2 during SM treatment, activates RIP1-and EDD-dependent TNFa production. SM-induced TNFa production has been studied in human cancer cell lines including breast, ovarian, and lung cancer cells. To validate the role of this RIP1-and EDD-dependent pathway in a previously established model of autocrine TNFa production, we tested the effect of Nec-1 and EDD knockdown on SM-induced apoptosis in the human breast cancer MDA-MB-231 cells. MDA-MB-231 cells undergo TNFa-dependent apoptosis with 100 nM SM-164. 20 As has been previously shown, knockdown of RIP1 is able to block SM-induced apoptosis (Figure 4a ). 7 However, neither Nec-1 treatment nor knockdown of EDD inhibited 100 nM SMinduced apoptosis (Figures 4a and b) . Surprisingly, we found that a 1000-fold lower dose of SM-164 (0.1 nM) is sufficient to induce TNFa-dependent apoptosis, with death blocked by a TNFa-neutralizing antibody or by caspase inhibition. This 'low dose' of SM induces RIP1 kinase-dependent cell death that is blocked by Nec-1 or by knockdown of EDD ( Figure 4c ).
To determine whether RIP1 kinase induces TNFa transcription in the MDA-MB-231 cell model, we measured TNFa mRNA levels by real-time PCR after treatment with either 0.1 nM or 100 nM SM-164. Both doses of SM increased TNFa transcription, but Nec-1 was only able to inhibit TNFa transcription in the cells stimulated with the low dose of SM ( Figure 4d ). The high, 100 nM dose of SM might be activating additional or nonspecific pathways that contribute to TNFa transcription and cell death in a RIP1 kinase-independent manner. Low-dose SM activates a specific RIP1 kinase-dependent mechanism of TNFa transcription.
A complex of EDD, RIP1, and the E3 ligase cIAP1 regulates TNFa production. To confirm the complex of EDD with RIP1, we examined the interaction of EDD and RIP1. We found that RIP1 coimmunoprecipitates with endogenous EDD in a constitutive manner and this binding is unaffected by RIP1 kinase activation with zVAD.fmk stimulation (Figure 5a ) or after SM treatment (Figure 5b) . Additionally, cIAP1, the target of SM, also coimmunoprecipitates with EDD unaffected by zVAD.fmk treatment (Figure 5c ).
To understand the interactions between the proteins in this complex, we determined the binding domains of RIP1 and cIAP1 to EDD. We tested the ability of EDD to bind RIP1 truncation mutants lacking the kinase domain (DKD), the death domain (DDD), and both the intermediate and death domains (DC). Each of these RIP1 truncation mutants expressed similarly, except for RIP1 DKD, which expressed as several bands. This is not due to loss of its kinase activity as the kinase inactive RIP1 K45M does not show this expression pattern (Supplementary Figure S2b) . Each of the RIP1 truncation constructs was able to coimmunoprecipitate with EDD, however, the amount of DKD in the immunocomplex was enriched compared with that of DC or DDD, suggesting that EDD predominantly interacts with the non-kinase domain of RIP1 (Figure 5d ).
EDD was expressed with cIAP1 or a related family member, XIAP, to confirm the specificity of binding. Antibodies against EDD coimmunoprecipitated cIAP1, but not XIAP (Figure 5e ). Testing the binding of cIAP1 deletion constructs indicated that BIR1 and BIR2 of cIAP1 are the minimal regions to coimmunoprecipitate with EDD, and are pulled down with the same efficiency as full-length cIAP1, suggesting that BIR1-BIR2 is sufficient for cIAP1 to bind EDD (Figure 5f ). There was no binding observed of the BIR3, CARD, or RINGcontaining constructs with EDD, indicating these domains do not interact with EDD. The BIR domains of cIAP1 also mediate its interactions with other proteins such as Traf2, Smac, and RIP1. 25, 26 EDD may act as a scaffold and bind to both cIAP1 and RIP1 kinase. This complex is important for regulating downstream signaling and the activation of TNFa transcription after zVAD.fmk or SM treatment.
A NF-jB independent mode of TNFa production. Both the canonical and non-canonical NF-kB pathways (NF-kB1 and NF-kB2, respectively) are activated by SM treatment; inhibition of NF-kB1 blocks TNFa production and cell death. 9,10 Loss of either cIAP1/2 or Traf2 stabilizes NIK, inducing the proteasomal processing and activation of NF-kB2. 9, 10, 27 Indeed, NF-kB2 is processed and activated within hours of SM-164 treatment in both 100 nM SM-164treated MDA-MB-231 cells and SM-treated L929 cells (Supplementary Figure S2c, Figure 6a ). Low-dose SM (0.1 nM) induced NF-kB2 processing in MDA-MB-231 cells as well, albeit with slower kinetics, likely due to the slower rate of cIAP1 degradation (Supplementary Figure S2c) . Importantly, Nec-1 had no effect on NF-kB2 processing in (Figure 6a, Supplementary Figure  S2c ). We were unable to detect the degradation of the inhibitor protein IkBa, a marker for NF-kB1 activation, under any stimulation (Figure 6a, Supplementary Figures S2c and  d) . As NF-kB is not activated in a RIP1 kinase-dependent manner after either zVAD.fmk or SM stimulation, NF-kB is unlikely to have a role in cell death or TNFa production as induced by zVAD.fmk or SM in L929 and J774 cells.
Although we did not observe RIP1 kinase-dependent activation of NF-kB, to verify that NF-kB does not have a role in zVAD.fmk-or SM-induced cell death, we knocked down NF-kB1 and NF-kB2 and tested the effect on cell death. Consistent with previously published work, 28 knockdown of NF-kB1 and NF-kB2 were not protective against necroptosis Figure S2e ). An inhibitor of NF-kB, SN50, 29 did not block zVAD.fmk-induced TNFa release in J774 cells (Supplementary Figure S2f) . Thus, we conclude that TNFa production induced by zVAD.fmk or SM is independent of NF-kB activity.
Lipopolysaccharide (LPS) is a pro-inflammatory stimulus found on the outer membrane of bacteria that activates TNFa transcription. Although LPS-induced TNFa is dependent on NF-kB, we tested the role of RIP1 and EDD in this pathway of TNFa production. Neither Nec-1 nor EDD knockdown was (Figure 6b ). Thus, RIP1 and EDD activation of TNFa production is distinct from NF-kBdependent pathways such as LPS-induced TNFa.
JNK signaling activates TNFa transcription downstream of RIP1 and EDD. Our siRNA screen identified a number of transcription factors as hits, including c-Jun and Sp1, both of which can be activated by JNK and MAPK signaling. 11, 30, 31 The importance of c-Jun/AP-1 in mediating TNFa transcription and cell death in response to zVAD.fmk has already been confirmed. 19, 28 Inhibition of JNK signaling blocks zVAD.fmk-, SM-, or Traf2 knockdown-induced necroptosis (Figure 6c ). The JNK inhibitor SP600125 blocks TNFa transcription induced by zVAD.fmk (Figure 6d) . Consistently, increased phosphorylation of JNK, indicating JNK kinase activation, was observed shortly after zVAD.fmk treatment. A definitive role for RIP1 kinase in activating JNK signaling has not been previously shown. We found that JNK phosphorylation after zVAD.fmk was attenuated in Nec-1-treated and EDD-knockdown cells (Figure 6e , Supplementary Figure S3a ). SM stimulation also activates JNK signaling in a manner dependent on RIP1 kinase and EDD (Supplementary Figure S3b) . Thus, RIP1 kinase and EDD activate JNK signaling to induce TNFa transcription.
TNFa itself can also activate JNK. Nec-1, however, has no effect on TNFa-induced JNK phosphorylation (Supplementary Figure S3c ). AIP1/Dab2IP, an ASK1 (JNK MAP3K) interacting protein, is reportedly a substrate of RIP1 after TNFa stimulation. 32 However, neither knockdown of AIP1/Dab2IP nor knockdown of ASK1 in our siRNA screen 11 protected against zVAD.fmk-induced cell death (Supplementary Figure S3d ). TNFa-induced JNK activation is RIP1 kinase independent and is activated by a separate pathway from zVAD.fmk treatment.
Analysis of our siRNA screen showed a significant enrichment of screen hits with Sp1-binding sites in their promoters, suggesting that Sp1 regulates transcription of genes required for necroptosis. 11 Consistent with this possibility, we found that knockdown of Sp1 specifically inhibits zVAD.fmk-or SM-induced cell death but not TNFainduced necroptosis, similar to EDD knockdown (Figure 6f ). Sp1 is able to synergize with c-Jun/AP-1 to activate TNFa transcription. 33 It is likely that both of these transcription factors are activated by JNK signaling downstream of RIP1 kinase and EDD to promote transcription of TNFa and possibly other genes in response to zVAD.fmk or SM stimulation.
Discussion
RIP1 kinase has been previously shown to specifically mediate TNFa-induced necroptosis downstream of TNFR1 by regulating the formation of complex IIb. 34, 35 In this study, we demonstrate a novel function of RIP1 kinase involving its interaction with EDD to regulate JNK activation and TNFa production. This pathway of TNFa production is activated specifically in response to treatment with zVAD.fmk or SM, or by knockdown of Traf2 and is distinguishable from the TNFa production pathway regulated by NF-kB that can be activated by TLR signaling (Figure 7) . We show that activation of this RIP1 kinase-dependent pathway leads to TNFa transcriptional activation. Our examination of this pathway indicates that RIP1 kinase and EDD mediate a common pathway of JNK activation and TNFa production in mouse and human systems, cell types such as macrophages and breast cancer cells, and in cells capable of undergoing either apoptosis or necroptosis. Our study suggests that RIP1 kinase not only regulates necroptosis downstream of TNFR1 signaling, but also has an important role in mediating the production of TNFa.
The role of RIP1 kinase in activating TNFa production is distinct from its role in mediating necroptosis. The function of RIP1 in TNFa production may provide a possible explanation for situations where Nec-1 was found to protect against apoptosis. MDA-MB-231 cells treated with a low dose of SM undergo typical TNFa-dependent apoptosis that can be blocked by Nec-1. This is due Nec-1 inhibiting the production of TNFa, which is required for apoptosis to occur after SM treatment, rather than a role of RIP1 kinase in mediating apoptosis itself. SM are currently in clinical trials as an anticancer treatment, indicating the role of RIP1 kinase in mediating the production of TNFa may be relevant for SM activity in vivo.
Both cIAP1/2 and Traf2 have been implicated as E3 ubiquitin ligases targeting RIP1. 5, 36 The finding that loss of either cIAP1/2 or Traf2 can activate RIP1 suggests that these proteins normally function to keep RIP1 inactive. traf2 À / À mice are normal at birth but become progressively runted and die prematurely with elevated serum TNFa levels. 24 The lethal phenotype is rescued by the loss of TNFa or TNFR1 in doubleknockout traf2 À / À tnf À / À or traf2 À / À tnfr1 À / À mice. 37 Our study suggests the possibility that RIP1 kinase regulated JNK activation mediates the production of TNFa in these mouse models of human diseases. The identification of SM and Traf2 knockdown as inducers of RIP1 kinase-mediated TNFa production suggests that RIP1 kinase activation might be regulated directly by ubiquitination by cIAP1/2 and/or Traf2. SMs, in addition to inducing the degradation of cIAP1 and cIAP2, and inhibit the activity of XIAP. 6, 20 Many of the cellular effects of SM in sensitizing cells to apoptosis have been attributed to the loss of caspase inhibition by XIAP. 8, 20 However, the effect of SM on RIP1 is likely due to the degradation of cIAP1/2, as the effect of SM on TNFa production was recapitulated in cIAP1-knockout cells but not XIAP-deficient cells. 10 Furthermore, EDD specifically interacts with cIAP1, so it is likely that they act in the same pathway.
EDD has been implicated in diverse cellular processes such as the DNA damage response and gene expression. EDD constitutively binds RIP1 kinase and the E3 ubiquitin ligase cIAP1. We propose that EDD functions as a scaffold protein in this pathway and interacts with the critical regulatory proteins. Similar to its role in mediating ATM phosphorylation of its substrates p53 and CHK2, [15] [16] [17] EDD may also mediate RIP1 phosphorylation of its substrate(s) in this pathway. We propose that EDD and RIP1 kinase mediate the activation of JNK signaling, potentially via recruitment of a RIP1 substrate that activates JNK to mediate multiple signaling pathways that are regulated by JNK. Future work is needed to determine how RIP1 kinase and EDD activate the JNK signaling pathway.
Materials and Methods
Gene knockdown experiments. L929 and MDA-MB-231 cells were reverse transfected with 25-50 nM siRNA (Dharmacon, Lafayette, CO, USA) in 384-well plates (Corning, Lowell, MA, USA) using HiPerfect transfection reagent (Qiagen, Gaithersburg, MD, USA), according to the manufacturers protocol. After 48 h of transfection, the cells were treated with zVAD.fmk, hTNFa, or SM-164. After 18-24 h, cell viability was determined by ATP assay using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Fitchburg, WI, USA). Stable knockdown cell lines were generated using a retroviral or lentiviral expression system to infect L929 or J774 cells, respectively. Expression of pSRP or pLKO.1 and packaging vectors were transfected into 293T cells to generate virus. L929 or J774 cells were infected with the virus and selected in medium containing 10 mg/ml or 2 mg/ml puromycin, respectively.
TNFa ELISA. J774 cells were plated 1 Â 10 5 cells/well in 24-well plates or L929 cells plated 4 Â 10 6 cells/10-cm plate, treated, and the cell supernatant collected or cells lysed in 1% Triton X-100 in PBS supplemented with Complete Protease Inhibitor (Roche, Indianapolis, IN, USA). Total protein levels were determined by Bradford protein assay (Bio-rad, Hercules, CA, USA). The levels of TNFa in cell lysate or supernatant were quantified using the mTNFa ELISA kit according to the manufacturers instructions (R&D Systems, Minneapolis, MN, USA).
Real-time PCR. To determine mRNA levels of TNFa in the cell, RNA was harvested according to the manufacturers protocol using the Qiagen RNeasy kit. One microgram of RNA was reverse transcribed with random hexamers and SuperScript II First Strand cDNA Synthesis System (Invitrogen, Carlsbad, CA, USA). The qPCR performed using 2 Â SYBR green master mix on the ABI 7900HT qPCR machine (Applied Biosystems, Carlsbad, CA, USA). Fold change in RNA was calculated using the comparative Ct method, normalizing to 18S rRNA or GAPDH control. Taqman probes were used for mTNFa and GAPDH (Applied Biosystems). Primers used are as follows: mTNFa (forward: 5 0 -CTTCTCAT TCCTGCTTGTGG-3 0 , reverse: 5 0 -ATGAGAGGGAGGCCATTTG-3 0 ), hTNFa (forward: 5 0 -GAGGCCAAGCCCTGGTATG-3 0 , reverse: 5 0 -CGGGCCGATTGATCT CAGC-3 0 PrimerBank ID 25952110b2), 38 or 18S rRNA (foward: 5 0 -CCTGCGGCTT AATTTGACTC-3 0 , reverse: 5 0 -AGACAAATCGCTCCACCAAC-3 0 ).
Coimmunoprecipitation. 293T cells were transfected by the calcium phosphate method and lysed after 24 h in 50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, and protease inhibitor cocktail (Roche). L929 cells were lysed in the buffer described except with 50 mM NaCl and 0.5% NP-40. The indicated antibody was used with protein A/G sepharose beads (Thermo Scientific, Waltham, MA, USA) for immunoprecipitation. IP was analyzed by SDS-PAGE and western blot.
Mass spectrometry of RIP1 interacting proteins. 293T cells were transfected by the calcium phosphate method with Flag-tagged RIP1 for 48 h. The cells were lysed (20 mM HEPES (pH 7.3), 5 mM EDTA, 150 mM NaCl, 5 mM NaF, 0.2 mM NaVO 3 , 1% Triton X-100, complete protease inhibitor cocktail) and immunoprecipitated using anti-Flag M2 agarose (Sigma, St. Louis, MO, USA). The beads were washed 5 Â with lysis buffer and the bound proteins eluted using 150 ng/ml Flag peptide. The eluted proteins were TCA precipitated and identified by mass spectrometry.
Expression vectors. The following plasmids were used: pcDNA3-Flag-RIP1 WT, DKD, DC, and DDD. RIP1 DKD was constructed using the following primers: 5 0 -CGAATCCGGAATTCCGGCCGACATTT-3 0 , and 5 0 -TGCAGACTCGAGGTTC TGGCTGACGTAAAT-3 0 to PCR a fragment from nt 843-2007 (NM_003804). RIP1 DDD was constructed using the forward primer 5 0 -ACGATGACGATAAAG AATTCAGGATGCAA-3 0 , and the reverse primer 5 0 -AGGTGCTCGAGCGTCAG ACTAGTGGTATT-3 0 to PCR a fragment from nt 1-1751 (NM_003804). RIP1 DC was constructed using the same forward primer as the DDD construct and the reverse primer 5 0 -TTCTTCTAATTGCTCGAGATAAAAAGGCCT-3 0 to PCR a fragment from nt 1-885 (NM_003804). Each of the PCR fragments was cloned into pcDNA3 using EcoRI and XhoI. pCMV-Tag2b-Flag-EDD (courtesy of C.K.W. Watts); Flag-XIAP; Flag-cIAP1, WT and the truncation constructs BIR1-2, BIR1-3, BIR3-RING, CARD-RING, RING. The shRNAs targeting EDD were inserted into the empty vector backbone (sequences: 5 0 -TGACAGCAGAACAACATAATT-3 0 in pSRP; 5 0 -GCTCGTCTTGATCTACTTTAT-3 0 in pLKO.1) (courtesy of K.P. Lu).
Antibodies and reagents. The primary antibodies used were anti-RIP1 (BD Biosciences, San Jose, CA, USA), anti-EDD (Novus Biologicals for IP, rat monoclonal raised against aa 459-794 for WB), anti-pJNK, anti-JNK, and anti-NF-kB2 (Cell Signaling), anti-NF-kB1, anti-IkBa, and anti-Traf2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cIAP1, anti-Flag M2 (Sigma), and anti-mouse and anti-human TNFa-neutralizing antibodies (R&D Systems). The compounds used were zVAD.fmk, hTNFa (Cell Sciences, Canton, MA, USA), SM-164 (kindly provided by Dr. Xiaomeng Wang), 20,21 7-Cl-O-Nec-1, 3 SP600125 (A.G. Scientific, San Diego, CA, USA), SN50/SN50M (Calbiochem, Darmstadt, Germany), and LPS (Sigma).
Tissue culture. L929, J774, and 293 T cells were maintained in DMEM supplemented with 10% FBS and penicillin and streptomycin (Invitrogen). MDA-MB-231 cells were grown in RPMI with 10% FBS, penicillin, and streptomycin (Invitrogen).
